drugset
drugset / Trial / NCT07646626

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

NCT07646626 ↗

Phase 2 Recruiting 150 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.
RandomizedSingle-groupOpen-labelTreatment

Summary

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.

Timeline

Start
2026-07-31
Primary completion
2027-06-30
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SSGJ-612 Unknown — —
Subject SSGJ-705 Unknown — —

Indications

cancer of unknown primary site